Lupus erythematosus - エリテマトーデス
relevance score : -100.0%
ReferencesCutaneous lupus erythematosus (CLE) を特定して分類することは、皮膚に関与する systemic lupus erythematosus と区別するという診断上の課題を引き起こします。最近の研究により、CLE の根底にある遺伝的、環境的、免疫学的要因が明らかになりました。特に薬物誘発は、CLE の最も重要な引き金の 1 つとして浮上しています。治療には、臨床試験で有効性が証明されている belimumab、rituximab、ustekinumab、anifrolumab、BIIB059 などの有望な生物学的製剤を含む局所療法および全身療法が含まれます。
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ではさまざまな皮膚の問題がみられますが、その一部は全身の健康問題と関連している可能性があります。急性 CLE (acute CLE, ACLE)、亜急性 CLE (sub‑acute CLE, SCLE)、慢性 CLE (chronic CLE, CCLE) の3つに分類されます。CCLE には discoid lupus erythematosus (DLE)、LE profundus (LEP)、chilblain cutaneous lupus、lupus tumidus が含まれます。
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus は、体のさまざまな部位に影響を及ぼす可能性がある自己免疫疾患のグループです。systemic lupus erythematosus (SLE) のように複数の臓器に関与するタイプもあれば、cutaneous lupus erythematosus (CLE) のように主に皮膚に影響するタイプもあります。私たちは臨床所見、組織検査、血液検査の組み合わせに基づいて、さまざまなタイプの CLE を分類していますが、個人差は大きいです。皮膚の問題は、日光への曝露、喫煙、特定の薬剤などの要因で起こりやすいです。
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
エリテマトーデス (lupus erythematosus) の原因はまだ明らかではありませんが、一卵性双生児で一方が罹患した場合、もう一方が罹患する確率は24%と報告されています。女性ホルモン、日光曝露、喫煙、ビタミンD欠乏、特定の感染症などがリスクを高めると考えられています。
治療にはNSAID、Corticosteroid(コルチコステロイド)、免疫抑制剤、Hydroxychloroquine(ヒドロキシクロロキン)、Methotrexate(メトトレキサート) が用いられます。Corticosteroidは効果的ですが、長期使用により副作用が出やすくなる点に注意が必要です。